Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00050154 | Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) | PHASE2 | COMPLETED | 82 | — | — | Jul 1, 2002 | May 1, 2006 | Apr 27, 2010 | - | — |
| Name | Type | Description |
|---|---|---|
| ZARNESTRA, tipifarnib, R115777 | DRUG | - |
Inclusion Criteria: * Pathological evidence of MDS * Not more than 1 prior cytotoxic treatment for MDS * Able to take oral study drug * Able to understand and provide signed informed consent Exclusion Criteria: * Refractory anemia (RA) or RA with excess of blasts (RAEB) or patients with RAEB with...